蛋白质芯片技术在乳腺癌新辅助化疗敏感与耐药差异蛋白筛查中的应用

目的 探讨蛋白质芯片技术在乳腺癌新辅助化疗敏感与耐药相关蛋白筛查中的价值.方法 提取10例TA方案(蒽环类+紫杉类)新辅助化疗患者术前空芯针穿刺标本的总蛋白;根据Miller & Payne分级将患者分为两组,将grade 4～5合并为化疗敏感组,grade 1～2合并为化疗耐药组,每组各有5例患者;应用抗体芯片与提取蛋白进行杂交,检测656种肿瘤相关蛋白表达水平;运用上述10例新辅助化疗患者的蛋白质表达结果筛选差异蛋白,并进行聚类分析.结果 空芯针穿刺活检可以为蛋白质芯片研究提供足够量的蛋白;分析化疗敏感组与化疗耐药组患者的蛋白表达谱差异,筛选出差异蛋白61个;以此差异蛋白为基础的聚类分析可将此两组乳腺癌标本聚成两类,准确率100%.结论 以蛋白质芯片技术为基础的分子分型对于预测乳腺癌新辅助化疗的敏感性有潜在的临床应用价值,但我们需要进一步的大样本研究验证此模型的稳定性和准确性.

Screening of sensitive and resistant related proteins in neo-adjuvant chemotherapy of breast cancer by protein microarray

Objective To screen the proteins that are related to the sensitivity or resistance of neoadjuvant chemotherapy in breast cancer and to provide molecular basis on the prediction model.Methods 10 patients were included in this study,who received neo-adjuvant taxane and anthracyclinebased chemotherapy,total protein was extracted from core needle biopsy samples of which 5 were sensitive to neo-adjuvant chemotherapy and 5 were resistant to neo-adjuvant chemotherapy.The sensitivity criterion was based on Miller & Payne grading,grade 4 and grade 5 were considered as sensitive,grade 1 and grade 2 were considered as resistant.Protein profiling was analyzed by antibody microarray,then screening of sensitive and resistant related proteins and clustering analysis were conducted.Results Core needle biopsy can provide sufficient protein to conduct the antibody microarray analysis,61 differentially expressed proteins were identified,10 patients were grouped as sensitive or resistant to neo-adjuvant chemotherapy by clustering analysis with an accuracy of 100%.Conclusion Molecular subtype of breast cancer based on proteomic analysis has a potential value to predict the sensitivity to neo-adjuvant chemotherapy.